IntrinsicIntrinsic

BEYOND MEAT, INC.

BYND
🏒 Food and Kindred Products

Business Operations Summary

Beyond Meat operates in the plant-based meat industry, offering a portfolio of plant-based meats and other innovative plant-based food and beverage products. The company's core business model revolves around creating plant-based alternatives to traditional animal-based meat products, focusing on beef, pork, and poultry platforms. Revenue is generated through sales to mainstream grocery, mass merchandiser, club store, natural retailer channels, and various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company also utilizes a direct-to-consumer (DTC) channel, Beyond Test Kitchen, launched in Q4 2025, for early access to new products. A significant portion of gross revenues, approximately 13% , 12% , and 12% in 2025, 2024, and 2023 respectively, is derived from one distributor, DOT Foods, Inc. .

The company's product portfolio is built around three core plant-based platforms: beef, pork, and poultry. Beef platform products, such as Beyond Burger IV and Beyond Beef IV, primarily use yellow pea protein, brown rice protein, faba bean protein, and red lentil protein, and are made with avocado oil, featuring 0 mg of cholesterol, no added antibiotics or hormones, and no GMOs. Beyond Steak was recognized in 2024 for meeting the American Diabetes Association's Better Choices for Life program nutritional guidelines. The pork platform includes Beyond Sausage, Beyond Breakfast Sausage Patties, Beyond Breakfast Sausage Links, and Beyond Sausage Crumbles, with protein from pea and rice protein. The 2024 Beyond Sausage IV also incorporates avocado oil and shares the same health attributes as the beef products. Poultry platform products, including Beyond Chicken Pieces, Beyond Chicken Tenders, and Beyond Chicken Nuggets, derive protein from pea protein, soy protein, and wheat gluten. In 2024, Beyond Sun Sausage was introduced as a distinct protein option, and in 2024 and 2025, value-added meals (VAM) like Beyond Bakes, Beyond Skillet Meals, and Beyond Bowls were launched. New products in 2025 included Beyond Ground, Beyond Steak Filet, and new Beyond Chicken Pieces, with Beyond Immerse, a plant-based protein drink, launched in early 2026 through the Beyond Test Kitchen DTC platform. The Beyond Burger alone accounted for approximately 50% , 52% , and 51% of gross revenues in 2025, 2024, and 2023, respectively.

For the fiscal year ended December 31, 2025, Beyond Meat reported net revenues of $275.496 million , a decrease from $326.452 million in 2024 and $343.376 million in 2023. Gross profit for 2025 was $7.646 million , down significantly from $41.699 million in 2024, resulting in a gross margin of 2.8% compared to 12.8% in the prior year. The company incurred a loss from operations of $333.621 million in 2025, an increase from a loss of $156.124 million in 2024. Net income for 2025 was $219.024 million , primarily driven by a $548.651 million gain on debt restructuring, net of exchange fees. Diluted EPS for 2025 was $(1.83) , compared to $(2.43) in 2024. Cash flows from operating activities were negative $144.9 million in 2025, compared to negative $98.8 million in 2024 and negative $107.8 million in 2023. As of December 31, 2025, cash and cash equivalents and restricted cash totaled $217.5 million , and long-term debt, net of debt discount, was $415.7 million .

Comparing 2025 to 2024, net revenues decreased by $50.956 million , or 15.6% . This was primarily due to a 15.9% decrease in the volume of products sold, partially offset by a 0.4% increase in net revenue per pound. U.S. retail net revenues decreased by 17.5% , U.S. foodservice by 18.1% , international retail by 11.1% , and international foodservice by 13.7% . Cost of goods sold decreased by $16.9 million , or 5.9% , but increased as a percentage of net revenues to 97.2% from 87.2% . Research and development expenses decreased by $4.9 million , or 17.5% , to $23.235 million . Selling, general and administrative (SG&A) expenses, excluding loss on write-down of assets held for sale, increased by $48.1 million , or 28.3% , to $217.757 million , representing 79.0% of net revenues. This increase was largely due to a $38.9 million litigation-related accrual, $8.1 million in legal fees for arbitration, and $8.0 million in higher share-based compensation, including $13.3 million related to the Exchange Offer.

Significant operational developments in 2025 included multiple workforce reductions: the February 2025 RIF impacting approximately 44 employees in North America and the EU, the China RIF affecting approximately 20 employees (95% of the China workforce) as operations in China ceased, and the August 2025 RIF reducing North American workforce by approximately 40 employees . These RIFs resulted in one-time cash charges of approximately $1.2 million , $0.4 million , and $1.1 million respectively. The cessation of China operations also led to $6.4 million in accelerated depreciation and $3.4 million in loss on write-down of assets held for sale. The company recorded an incremental provision for excess and obsolete inventory of $2.4 million due to SKU rationalization and product line discontinuation. A $51.3 million impairment loss on long-lived assets was recorded in Q3 2025. The company also completed an Exchange Offer in October 2025, exchanging $1,120,541,000 aggregate principal amount of 2027 Notes for $209,721,000 in 2030 Notes and 317,834,446 shares of common stock, resulting in a $548.7 million gain on debt restructuring. A Loan and Security Agreement was entered into on May 7, 2025, providing a $100.0 million Delayed Draw Term Loan Facility, with $40.0 million drawn on June 26, 2025, and $60.0 million drawn on September 18, 2025.

Business Outlook & Future Growth Drivers

Management expects interest expense to increase from current levels in 2026 due to the amortization of the issuance date fair value of the 2030 Notes Embedded Derivative liability and amortization of debt discount, as well as interest expense associated with the Delayed Draw Term Loans . The company also anticipates recording significant mark-to-market adjustments from the remeasurement of derivatives and other liabilities carried at fair value at each reporting period . For the year ending December 31, 2026, the company expects to record approximately $2.2 million in accelerated depreciation for remaining leasehold improvement assets in China, unrelated to assets held for sale .

The company intends to pursue top-line growth by expanding its retail and foodservice footprint and building market share through distribution expansion, continued innovation and commercialization of new products, including in adjacent categories outside of core meat analogue offerings . This includes optimizing price pack architecture, increasing penetration across channels and geographies, and expanding direct-to-consumer (DTC) channels such as Beyond Test Kitchen, which was launched in the fourth quarter of 2025 . The Beyond Test Kitchen platform allows for early access to new plant-based protein products, generally for a limited time, to test products directly with consumers and gather feedback before potential broader release . The company believes increased global distribution, supported by existing and new partnerships, will lead to growing consumer awareness and demand for nutritious, convenient, and high-protein plant-based foods, increasing the overall size of the plant-based foods category and improving market share .

The company plans to expand its product offerings by improving existing product formulations and creating new products that broaden the portfolio . This includes continually refining plant-based meat products to enhance taste, texture, aroma, appearance, and nutrition, while lowering production costs . Investment in research and development will continue to innovate within the core plant-based beef, pork, and poultry platforms . Additionally, as protein demand grows and fiber becomes a key macronutrient trend, the company intends to broaden its product portfolio to include plant-based foods and beverages focusing on product intrinsics and compelling macronutrients . An example of this expansion is the introduction in January 2026 of Beyond Immerse, a plant-based protein beverage, through the Beyond Test Kitchen DTC platform .

Operationally, the company is continually reviewing opportunities to optimize its manufacturing capacity across its network, aiming to increase overall equipment effectiveness, improve asset utilization, leverage internal manufacturing and co-manufacturer networks, reduce material and logistics costs, and invest in new processes and business management systems to increase automation, improve operating efficiency, and enable greater scalability . The company's cost-reduction initiatives and Global Operations Review, initiated in 2023, involve narrowing commercial focus to anticipated growth opportunities and accelerating activities that prioritize gross margin expansion and cash generation . These efforts include exiting or discontinuing select product lines, changes to pricing architecture, cash-accretive inventory reduction initiatives, and further optimization of manufacturing capacity and real estate footprint .

Planned capital allocation includes continued investment in research and development, although expenses in this area decreased in 2025 and are expected to decrease in 2026 as the company focuses on reducing and optimizing operating expenses . The company expects to raise significant additional capital through the issuance of additional equity and/or debt securities, and/or incur other indebtedness, some or all of which may be secured, to continue funding operations and repaying indebtedness in the future . As of December 31, 2025, approximately $2,000 in capacity remained for further sale of shares under the ATM Program, but the company has suspended its use due to not timely filing its 10-K .

Structural headwinds and execution risks management explicitly flagged include ongoing and persistent declines in demand in the plant-based meat category and for the company's products, particularly in the refrigerated subsegment . Adverse changes in consumer tastes and perceptions about plant-based meat, broad macroeconomic headwinds including inflation, high interest rates, waning consumer confidence, and potential recessionary concerns in certain geographic regions are also noted . Increased competitive activity in the plant-based meat category, global events such as the ongoing war between Russia and Ukraine and the escalating armed conflict in the Middle East, and current and proposed future tariffs are identified as factors that could impact raw material availability and product distribution . Regulatory uncertainty about labeling and marketing practices in Europe could negatively impact the ability to expand product distribution . The plant-based meat sector's premium pricing relative to animal protein has caused and could continue to cause consumers to trade down into cheaper forms of protein .

Major Risk Factors & Challenges

The company faces material risks including ongoing and persistent declines in demand in the plant-based meat category, exacerbated by macroeconomic trends such as inflation and high interest rates, which have negatively impacted sales and profitability . Geopolitical instability, including the ongoing war between Russia and Ukraine and the escalating armed conflict in the Middle East, poses risks to supply chains, costs, and global economic stability . Regulatory risks are significant, with potential changes in U.S. and international laws regarding the labeling and naming of plant-based meat products, such as the Real MEAT Act in the U.S. or similar legislation in France, Italy, Poland, Belgium, Switzerland, and South Africa, which could require product relabeling, modify marketing strategies, or lead to enforcement actions and recalls . Operational risks include reliance on a limited number of third-party suppliers for key raw materials like pea protein and avocado oil, exposing the company to supply disruptions, price volatility, and quality issues . The company has identified material weaknesses in internal control over financial reporting related to accounting for non-routine and complex transactions and the valuation of inventory, including the provision for excess and obsolete inventory, which could impair accurate financial reporting and investor confidence . Furthermore, the company is subject to litigation risks, including a trademark infringement lawsuit where a jury awarded $23.5 million in actual damages and $15.4 million in disgorgement of profits . The company's common stock is also at risk of delisting from Nasdaq due to its closing bid price being below the minimum $1.00 per share requirement for 30 consecutive business days .

Management Priorities & Sentiments

Management's message to shareholders emphasizes a pivot towards sustainable long-term growth, supported by three pillars: driving margin recovery and operating expense reduction through lean value streams, inventory reduction and cash flow generation, and focusing on near-term retail and foodservice growth drivers while supporting key strategic long-term partners and opportunities . The company has undertaken significant cost-reduction initiatives, including multiple workforce reductions in 2023 and 2025, and the cessation of operational activities in China by the end of 2025 . Management expects to record approximately $2.2 million in accelerated depreciation for remaining leasehold improvement assets in China for the year ending December 31, 2026 . Strategic priorities include expanding distribution channels, such as the Beyond Test Kitchen DTC platform, to test new products and gather consumer feedback , and broadening the product portfolio to include plant-based foods and beverages beyond meat analogues, exemplified by the January 2026 introduction of Beyond Immerse, a plant-based protein drink . The company also aims to optimize manufacturing capacity, improve asset utilization, and reduce material and logistics costs .

References

  1. [1] Item 7, MD&A β€” Overview
  2. [2] Item 7, MD&A β€” Overview
  3. [3] Item 7, MD&A β€” Overview
  4. [4] Item 7, MD&A β€” Overview
  5. [5] Item 7, MD&A β€” Overview
  6. [6] Item 7, MD&A β€” Overview
  7. [7] Item 7, MD&A β€” Overview
  8. [8] Item 7, MD&A β€” Overview
  9. [9] Item 7, MD&A β€” Overview
  10. [10] Item 7, MD&A β€” Overview
  11. [11] Item 7, MD&A β€” Overview
  12. [12] Item 7, MD&A β€” Overview
  13. [13] Item 7, MD&A β€” Overview
  14. [14] Item 7, MD&A β€” Overview
  15. [15] Item 7, MD&A β€” Overview
  16. [16] Item 7, MD&A β€” Overview
  17. [17] Item 7, MD&A β€” Overview
  18. [18] Item 7, MD&A β€” Overview
  19. [19] Item 7, MD&A β€” Overview
  20. [20] Item 7, MD&A β€” Overview
  21. [21] Item 7, MD&A β€” Overview
  22. [22] Item 1, Business β€” Customers
  23. [23] Item 1, Business β€” Customers
  24. [24] Item 1, Business β€” Customers
  25. [25] Item 1, Business β€” Customers
  26. [26] Item 1, Business β€” Products
  27. [27] Item 1, Business β€” Products
  28. [28] Item 1, Business β€” Products
  29. [29] Item 1, Business β€” Products
  30. [30] Item 1, Business β€” Products
  31. [31] Item 1, Business β€” Products
  32. [32] Item 1, Business β€” Products
  33. [33] Item 1, Business β€” Products
  34. [34] Item 1, Business β€” Products
  35. [35] Item 1, Business β€” Products
  36. [36] Item 1, Business β€” Products
  37. [37] Item 1, Business β€” Products
  38. [38] Item 1, Business β€” Products
  39. [39] Item 1, Business β€” Products
  40. [40] Item 1, Business β€” Products
  41. [41] Item 1, Business β€” Products
  42. [42] Item 1, Business β€” Products
  43. [43] Item 1, Business β€” Products
  44. [44] Item 1, Business β€” Products
  45. [45] Item 1, Business β€” Products
  46. [46] Item 1, Business β€” Products
  47. [47] Item 1, Business β€” Products
  48. [48] Item 1, Business β€” Products
  49. [49] Item 1, Business β€” Products
  50. [50] Item 1, Business β€” Products
  51. [51] Item 1, Business β€” Products
  52. [52] Item 1, Business β€” Products
  53. [53] Item 1, Business β€” Products
  54. [54] Item 1, Business β€” Products
  55. [55] Item 1, Business β€” Products
  56. [56] Item 1, Business β€” Products
  57. [57] Item 1, Business β€” Products
  58. [58] Item 1, Business β€” Products
  59. [59] Item 1, Business β€” Products
  60. [60] Item 1, Business β€” Products
  61. [61] Item 1, Business β€” Products
  62. [62] Item 1, Business β€” Products
  63. [63] Item 1, Business β€” Products
  64. [64] Item 1, Business β€” Products
  65. [65] Item 1, Business β€” Products
  66. [66] Item 1, Business β€” Products
  67. [67] Item 1, Business β€” Products
  68. [68] Item 1, Business β€” Products
  69. [69] Item 1, Business β€” Products
  70. [70] Item 1, Business β€” Products
  71. [71] Item 1, Business β€” Products
  72. [72] Item 1, Business β€” Products
  73. [73] Item 1, Business β€” Products
  74. [74] Item 1, Business β€” Products
  75. [75] Item 1, Business β€” Products
  76. [76] Item 1, Business β€” Products
  77. [77] Item 1, Business β€” Products
  78. [78] Item 1, Business β€” Products
  79. [79] Item 1, Business β€” Products
  80. [80] Item 1, Business β€” Products
  81. [81] Item 1, Business β€” Products
  82. [82] Item 1, Business β€” Products
  83. [83] Item 1, Business β€” Products
  84. [84] Item 1, Business β€” Products
  85. [85] Item 1, Business β€” Products
  86. [86] Item 1, Business β€” Products
  87. [87] Item 1, Business β€” Products
  88. [88] Item 1, Business β€” Products
  89. [89] Item 1, Business β€” Products
  90. [90] Item 1, Business β€” Products
  91. [91] Item 1, Business β€” Products
  92. [92] Item 1, Business β€” Products
  93. [93] Item 1, Business β€” Products
  94. [94] Item 1, Business β€” Products
  95. [95] Item 1, Business β€” Products
  96. [96] Item 1, Business β€” Products
  97. [97] Item 1, Business β€” Products
  98. [98] Item 1, Business β€” Products
  99. [99] Item 1, Business β€” Products
  100. [100] Item 1A, Risk Factors β€” Risks Related to Our Products
  101. [101] Item 1A, Risk Factors β€” Risks Related to Our Products
  102. [102] Item 1A, Risk Factors β€” Risks Related to Our Products
  103. [103] Item 7, MD&A β€” Results of Operations
  104. [104] Item 7, MD&A β€” Results of Operations
  105. [105] Item 7, MD&A β€” Results of Operations
  106. [106] Item 7, MD&A β€” Results of Operations
  107. [107] Item 7, MD&A β€” Results of Operations
  108. [108] Item 7, MD&A β€” Results of Operations
  109. [109] Item 7, MD&A β€” Results of Operations
  110. [110] Item 7, MD&A β€” Results of Operations
  111. [111] Item 7, MD&A β€” Results of Operations
  112. [112] Item 7, MD&A β€” Results of Operations
  113. [113] Item 7, MD&A β€” Results of Operations
  114. [114] Item 7, MD&A β€” Results of Operations
  115. [115] Item 7, MD&A β€” Results of Operations
  116. [116] Item 7, MD&A β€” Overview
  117. [117] Item 7, MD&A β€” Overview
  118. [118] Item 7, MD&A β€” Overview
  119. [119] Item 1A, Risk Factors β€” Risks Related to Our Lease Obligations, Indebtedness, Financial Position and Need for Additional Capital
  120. [120] Item 1A, Risk Factors β€” Risks Related to Our Lease Obligations, Indebtedness, Financial Position and Need for Additional Capital
  121. [121] Item 7, MD&A β€” Net Revenues
  122. [122] Item 7, MD&A β€” Net Revenues
  123. [123] Item 7, MD&A β€” Net Revenues
  124. [124] Item 7, MD&A β€” Net Revenues
  125. [125] Item 7, MD&A β€” Net Revenues
  126. [126] Item 7, MD&A β€” Net Revenues
  127. [127] Item 7, MD&A β€” Net Revenues
  128. [128] Item 7, MD&A β€” Net Revenues
  129. [129] Item 7, MD&A β€” Cost of Goods Sold
  130. [130] Item 7, MD&A β€” Cost of Goods Sold
  131. [131] Item 7, MD&A β€” Cost of Goods Sold
  132. [132] Item 7, MD&A β€” Cost of Goods Sold
  133. [133] Item 7, MD&A β€” Research and Development Expenses
  134. [134] Item 7, MD&A β€” Research and Development Expenses
  135. [135] Item 7, MD&A β€” Research and Development Expenses
  136. [136] Item 7, MD&A β€” SG&A Expenses
  137. [137] Item 7, MD&A β€” SG&A Expenses
  138. [138] Item 7, MD&A β€” SG&A Expenses
  139. [139] Item 7, MD&A β€” SG&A Expenses
  140. [140] Item 7, MD&A β€” SG&A Expenses
  141. [141] Item 7, MD&A β€” SG&A Expenses
  142. [142] Item 7, MD&A β€” SG&A Expenses
  143. [143] Item 7, MD&A β€” SG&A Expenses
  144. [144] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  145. [145] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  146. [146] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  147. [147] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  148. [148] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  149. [149] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  150. [150] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  151. [151] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  152. [152] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  153. [153] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  154. [154] Item 7, MD&A β€” Loss from Impairment of Long-Lived Assets
  155. [155] Item 7, MD&A β€” Convertible Notes and Exchange Offer
  156. [156] Item 7, MD&A β€” Convertible Notes and Exchange Offer
  157. [157] Item 7, MD&A β€” Convertible Notes and Exchange Offer
  158. [158] Item 7, MD&A β€” Total Other Income (Expense), Net
  159. [159] Item 1A, Risk Factors β€” Risks Related to Our Lease Obligations, Indebtedness, Financial Position and Need for Additional Capital
  160. [160] Item 1A, Risk Factors β€” Risks Related to Our Lease Obligations, Indebtedness, Financial Position and Need for Additional Capital
  161. [161] Item 1A, Risk Factors β€” Risks Related to Our Lease Obligations, Indebtedness, Financial Position and Need for Additional Capital
  162. [162] Item 7, MD&A β€” Total Other Income (Expense), Net
  163. [163] Item 7, MD&A β€” Total Other Income (Expense), Net
  164. [164] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  165. [165] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  166. [166] Item 1, Business β€” Long-Term Growth Strategy
  167. [167] Item 1, Business β€” Long-Term Growth Strategy
  168. [168] Item 1, Business β€” Long-Term Growth Strategy
  169. [169] Item 1, Business β€” Long-Term Growth Strategy
  170. [170] Item 1, Business β€” Long-Term Growth Strategy
  171. [171] Item 1, Business β€” Long-Term Growth Strategy
  172. [172] Item 1, Business β€” Long-Term Growth Strategy
  173. [173] Item 1, Business β€” Long-Term Growth Strategy
  174. [174] Item 1, Business β€” Products
  175. [175] Item 1, Business β€” Long-Term Growth Strategy
  176. [176] Item 1, Business β€” Cost-Reduction Initiatives and Global Operations Review
  177. [177] Item 1, Business β€” Cost-Reduction Initiatives and Global Operations Review
  178. [178] Item 7, MD&A β€” Research and Development Expenses
  179. [179] Item 1A, Risk Factors β€” Risks Related to Our Lease Obligations, Indebtedness, Financial Position and Need for Additional Capital
  180. [180] Item 7, MD&A β€” ATM Program
  181. [181] Item 7, MD&A β€” ATM Program
  182. [182] Item 1A, Risk Factors β€” Risks Related to Our Business
  183. [183] Item 1A, Risk Factors β€” Risks Related to Our Business
  184. [184] Item 1A, Risk Factors β€” Risks Related to Our Business
  185. [185] Item 1A, Risk Factors β€” Risks Related to Our Business
  186. [186] Item 1A, Risk Factors β€” Risks Related to Our Business
  187. [187] Item 1A, Risk Factors β€” Risks Related to Regulatory and Legal Compliance Matters, Litigation and Legal Proceedings
  188. [188] Item 1A, Risk Factors β€” Risks Related to Our Business
  189. [189] Item 1A, Risk Factors β€” Risks Related to Being a Public Company
  190. [190] Item 1A, Risk Factors β€” Risks Related to Our Intellectual Property, Information Technology, Cybersecurity and Privacy
  191. [191] Item 1A, Risk Factors β€” Risks Related to Our Intellectual Property, Information Technology, Cybersecurity and Privacy
  192. [192] Item 1A, Risk Factors β€” Risks Related to Our Intellectual Property, Information Technology, Cybersecurity and Privacy
  193. [193] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  194. [194] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
  195. [195] Item 7, MD&A β€” Overview
  196. [196] Item 7, MD&A β€” Overview
  197. [197] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  198. [198] Item 7, MD&A β€” Cost-Reduction Initiatives and Global Operations Review
  199. [199] Item 7, MD&A β€” Overview
  200. [200] Item 7, MD&A β€” Overview
  201. [201] Item 1, Business β€” Long-Term Growth Strategy

Report on May 20, 2026